Results 131 to 140 of about 1,486,273 (317)
Quality of life in patients receiving platinum based chemotherapy for advanced non-small cell lung cancer. [PDF]
, 2006 Quality of life in patients receiving platinum based chemotherapy for advanced non-small cell lung cancer. Lung cancer is the cause of 34,000 deaths in the UK each year, with a five year survival rate of only 7.5%.
Leary, A.
core
Molecular Oncology, EarlyView.This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source
, 2011 To evaluate the efficacy of intravenous ramosetron plus dexamethasone for the prevention of acute chemotherapy- induced nausea and vomiting. Cancer patients scheduled to receive chemotherapy containing either of the four drugs ( cisplatin, doxorubicin ...
何景良;蘇五洲;謝瑞坤;林宗哲;趙祖怡 +1 more
core +1 more source
The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer
Molecular Oncology, EarlyView.Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad +2 more
wiley +1 more source
Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy
Molecular Oncology, EarlyView.We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen +19 more
wiley +1 more source
Breast Tumor Susceptibility to Chemotherapy via Support Vector Machines [PDF]
, 2003 Support vector machines (SVMs), utilizing RNA signature measurements, were used to generate a classi er to distinguish breast cancer patients that are partial-responders to chemotherapy treatment, from patients that are nonresponders.
Mangasarian, Olvi, Fung, Glenn
core
Molecular Oncology, EarlyView.High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
Molecular Oncology, EarlyView.In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico +5 more
wiley +1 more source
, 2017 BACKGROUND: Surgical resection is the only curative treatment for extrahepatic bile duct cancer. Additionally, the recurrence rate after curative surgery is relatively high, requiring adjuvant therapy.
박승우 +7 more
core +1 more source
Molecular Oncology, EarlyView.Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez +5 more
wiley +1 more source